[National Strategic Promotion for Large-Scale Clinical Cancer Research]
1Foundation for Promotion of Cancer Research, Former Director General of the Health Service Bureau Ministry of Health, Labour and Welfare Japan.
Abstract:
The number of clinical research by clinical cancer study groups has been decreasing this year in Japan. They say the reason is the abolition of donations to the groups from the pharmaceutical companies after the Diovan scandal. But I suppose fundamental problem is that government-supported large-scale clinical cancer study system for evidence based medicine (EBM) has not been fully established. An urgent establishment of the system based on the national strategy is needed for the cancer patients and the public health promotion.
Insights
Clinical cancer research in Japan is declining due to pharmaceutical donation changes. An established, government-funded system for large-scale clinical cancer studies is urgently needed for evidence-based medicine and patient health.
Area of Science:
- Oncology
- Clinical Research
- Evidence-Based Medicine
Context:
- Declining clinical cancer research activity in Japan.
- Impact of pharmaceutical company donation abolition following the Diovan scandal.
- Inadequate governmental support for large-scale clinical cancer studies.
Purpose:
- To highlight the decrease in clinical cancer research in Japan.
- To identify the contributing factors to this decline.
- To advocate for the establishment of a national system for clinical cancer research.
Summary:
- The number of clinical cancer studies in Japan has decreased, attributed to the cessation of pharmaceutical donations post-Diovan scandal.
- A fundamental issue is the lack of a fully established, government-supported large-scale clinical cancer study system.
- The abstract argues for the urgent creation of such a system as a national strategy.
Impact:
- Potential negative consequences for cancer patients due to reduced research.
- Hindrance to public health promotion and advancements in evidence-based cancer care.
- The need for strategic governmental investment to revitalize clinical cancer research infrastructure.
More Related Videos
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...